SOURCE: Oragenics, Inc.

December 14, 2007 10:08 ET

Oragenics to Receive European Patent for Its IVIAT™ Biomarker Technology

ALACHUA, FL--(Marketwire - December 14, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases and cancer, announced today that it has been notified by the European Patent Office of its intention to grant a European patent for "Identification of Microbial Polynucleotides Expressed During Infection of a Host" or the In Vivo Induced Antigen Technology, IVIAT™. Oragenics intends to validate the patent in key European jurisdictions.

IVIAT™ is a unique discovery platform designed to identify genes of pathogenic bacteria that are specifically present when humans have infections. Dr. Robert Zahradnik, Oragenics' President and CEO, stated, "The IVIAT™ technology has already proven its ability to identify novel targets for such infectious agents as Vibrio cholerae (cholera), Escherichia coli (E. coli) and Pseudomonas aeruginosa, which causes infections in persons with compromised immune systems in addition to causing one out of ten hospital acquired infections. These gene targets offer the promise of new diagnostic tests and vaccines. The granting of this EU patent will further add to our growing international patent portfolio." Oragenics is currently investigating the suitability of its proprietary tuberculosis (TB) biomarkers, identified utilizing the IVIAT™ platform technology, for incorporation into an improved point-of-care TB test, which will to address a well recognized and very critical worldwide need.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact Information